<DOC>
	<DOCNO>NCT00999349</DOCNO>
	<brief_summary>Silymarin , flavonolignan complex isolate Silybum marianum , strong antioxidant , hepatoprotective iron chelating activity . The present study design investigate therapeutic activity orally administer silymarin patient thalassemia major conventional iron chelation therapy . A 6-month randomized , double-blind , clinical trial conduct 140 beta-thalassemia major patient two well-matched group . Patients randomize receive silymarin tablet ( 140 mg ) three time day plus conventional desferrioxamine therapy therapy placebo tablet instead silymarin . Clinical laboratory test iron status liver function assess begin end trial .</brief_summary>
	<brief_title>Therapeutic Effects Silymarin Patients With B-thalassemia Major</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Presence major Betathalassemia Age 12 year old Iron overload condition ( serum ferritin level 10005000 ng/mL ) Regular desferrioxamine administration ( 50 mg/kg ) Continuous blood transfusion Negative CRP test Exclusion criterion : Hepatitis B C infection Positive HIV test Chronic renal heart failure Iron chelating therapy iron chelators</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>iron overload condition</keyword>
	<keyword>regular desferrioxamine administration</keyword>
	<keyword>receive continuous blood transfusion</keyword>
</DOC>